125 related articles for article (PubMed ID: 7109625)
21. Purification of soluble human melanoma-associated antigens.
Roth JA; Slocum HK; Pellegrino MA; Holmes EC; Reisfeld RA
Cancer Res; 1976 Jul; 36(7 PT 1):2360-4. PubMed ID: 776393
[TBL] [Abstract][Full Text] [Related]
22. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
23. Detection of human malignant melanoma antigens by immunofluorescence and autologous postimmune antimelanoma sera.
Leong SP
Ann N Y Acad Sci; 1983; 420():237-50. PubMed ID: 6372592
[TBL] [Abstract][Full Text] [Related]
24. [Skin reactions of delayed hypersensitivity in melanoblastoma].
Ryzhkov VI; Potapenkova LS; Korosteleva TA; Khachaturian LM
Vopr Onkol; 1979; 25(4):3-6. PubMed ID: 433214
[TBL] [Abstract][Full Text] [Related]
25. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma.
Bystryn JC; Oratz R; Roses D; Harris M; Henn M; Lew R
Cancer; 1992 Mar; 69(5):1157-64. PubMed ID: 1739915
[TBL] [Abstract][Full Text] [Related]
26. Melanoma antigens that produce cell-mediated immune responses in melanoma patients: joint U.S.-U.S.S.R. study.
Gorodilova VV; Hollinshead A
Science; 1975 Oct; 190(4212):391-2. PubMed ID: 1179218
[No Abstract] [Full Text] [Related]
27. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.
Hersey P; Menzies SW; Coventry B; Nguyen T; Farrelly M; Collins S; Hirst D; Johnson H
Cancer Immunol Immunother; 2005 Mar; 54(3):208-18. PubMed ID: 15449035
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for melanoma.
Vaisrub S
JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
[No Abstract] [Full Text] [Related]
30. Purification and immunologic evaluation of human melnoma-associated antigens.
McCabe RP; Ferrone S; Pellegrino MA; Kern DH; Holmes EC; Reisfeld RA
J Natl Cancer Inst; 1978 Apr; 60(4):773-7. PubMed ID: 75978
[TBL] [Abstract][Full Text] [Related]
31. Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics.
Shiku H; Takahashi T; Resnick LA; Oettgen HF; Old LJ
J Exp Med; 1977 Mar; 145(3):784-9. PubMed ID: 233917
[TBL] [Abstract][Full Text] [Related]
32. Comparative evaluation of lymphocyte subpopulations, delayed cutaneous hypersensitivity reactions and autoantibody formation in cancer patients.
Pichler WJ; Stingl G; Wagner G; Micksche M; Neumann H; Knapp W
Osterr Z Onkol; 1977 Nov; 4(5-6):110-7. PubMed ID: 202907
[No Abstract] [Full Text] [Related]
33. Immunologic evaluation of the cancer patient during immunotherapy.
Boehm OR; Boehm BJ; Jewell WR; Humphrey LJ
Natl Cancer Inst Monogr; 1972 Dec; 35():403-8. PubMed ID: 4633407
[No Abstract] [Full Text] [Related]
34. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
35. Humoral response of melanoma patients to two different tumor-associated antigens.
Chee DO; Gupta RK; Morton DL
J Surg Oncol; 1983 Aug; 23(4):228-35. PubMed ID: 6876798
[TBL] [Abstract][Full Text] [Related]
36. Approaches for the isolation of biologically functional tumor-associated antigens.
Reisfeld RA; David GS; Ferrone S; Pellegrino MA; Holmes EC
Cancer Res; 1977 Aug; 37(8 Pt 2):2860-5. PubMed ID: 301432
[TBL] [Abstract][Full Text] [Related]
37. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
38. [Cutaneous, cellular immunity in malignant melanoma].
Kehrer HC
Wien Klin Wochenschr; 1991; 103(13):396-7. PubMed ID: 1897233
[No Abstract] [Full Text] [Related]
39. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
Cassel WA; Murray DR; Torbin AH; Olkowski ZL; Moore ME
Cancer; 1977 Aug; 40(2):672-9. PubMed ID: 196739
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens.
Bystryn JC
Ann N Y Acad Sci; 1993 Aug; 690():190-203. PubMed ID: 8368738
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
